These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 31897526)

  • 1. Luseogliflozin increases beta cell proliferation through humoral factors that activate an insulin receptor- and IGF-1 receptor-independent pathway.
    Shirakawa J; Tajima K; Okuyama T; Kyohara M; Togashi Y; De Jesus DF; Basile G; Kin T; Shapiro AMJ; Kulkarni RN; Terauchi Y
    Diabetologia; 2020 Mar; 63(3):577-587. PubMed ID: 31897526
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of the antitumor drug OSI-906, a dual inhibitor of IGF-1 receptor and insulin receptor, on the glycemic control, β-cell functions, and β-cell proliferation in male mice.
    Shirakawa J; Okuyama T; Yoshida E; Shimizu M; Horigome Y; Tuno T; Hayasaka M; Abe S; Fuse M; Togashi Y; Terauchi Y
    Endocrinology; 2014 Jun; 155(6):2102-11. PubMed ID: 24712877
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Linagliptin Ameliorates Hepatic Steatosis via Non-Canonical Mechanisms in Mice Treated with a Dual Inhibitor of Insulin Receptor and IGF-1 Receptor.
    Okuyama T; Shirakawa J; Tajima K; Ino Y; Vethe H; Togashi Y; Kyohara M; Inoue R; Miyashita D; Li J; Goto N; Ichikawa T; Yamasaki S; Ohnuma H; Takayanagi R; Kimura Y; Hirano H; Terauchi Y
    Int J Mol Sci; 2020 Oct; 21(21):. PubMed ID: 33105604
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Protective effects of SGLT2 inhibitor luseogliflozin on pancreatic β-cells in obese type 2 diabetic db/db mice.
    Okauchi S; Shimoda M; Obata A; Kimura T; Hirukawa H; Kohara K; Mune T; Kaku K; Kaneto H
    Biochem Biophys Res Commun; 2016 Feb; 470(3):772-782. PubMed ID: 26505796
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Epithelial-mesenchymal transition predicts sensitivity to the dual IGF-1R/IR inhibitor OSI-906 in hepatocellular carcinoma cell lines.
    Zhao H; Desai V; Wang J; Epstein DM; Miglarese M; Buck E
    Mol Cancer Ther; 2012 Feb; 11(2):503-13. PubMed ID: 22161861
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Protective effects of the SGLT2 inhibitor luseogliflozin on pancreatic β-cells in db/db mice: The earlier and longer, the better.
    Kimura T; Obata A; Shimoda M; Okauchi S; Kanda-Kimura Y; Nogami Y; Moriuchi S; Hirukawa H; Kohara K; Nakanishi S; Mune T; Kaku K; Kaneto H
    Diabetes Obes Metab; 2018 Oct; 20(10):2442-2457. PubMed ID: 29873444
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dipeptidyl peptidase-4 inhibitor and sodium-glucose cotransporter 2 inhibitor additively ameliorate hepatic steatosis through different mechanisms of action in high-fat diet-fed mice.
    Iwamoto Y; Kimura T; Dan K; Iwamoto H; Sanada J; Fushimi Y; Katakura Y; Shimoda M; Nogami Y; Shirakiya Y; Nakanishi S; Mune T; Kaku K; Kaneto H
    Diabetes Obes Metab; 2024 Jun; 26(6):2339-2348. PubMed ID: 38504118
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Insulin Signaling Regulates the FoxM1/PLK1/CENP-A Pathway to Promote Adaptive Pancreatic β Cell Proliferation.
    Shirakawa J; Fernandez M; Takatani T; El Ouaamari A; Jungtrakoon P; Okawa ER; Zhang W; Yi P; Doria A; Kulkarni RN
    Cell Metab; 2017 Apr; 25(4):868-882.e5. PubMed ID: 28286049
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Glucose Induces Mouse β-Cell Proliferation via IRS2, MTOR, and Cyclin D2 but Not the Insulin Receptor.
    Stamateris RE; Sharma RB; Kong Y; Ebrahimpour P; Panday D; Ranganath P; Zou B; Levitt H; Parambil NA; O'Donnell CP; García-Ocaña A; Alonso LC
    Diabetes; 2016 Apr; 65(4):981-95. PubMed ID: 26740601
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Overcoming IGF1R/IR resistance through inhibition of MEK signaling in colorectal cancer models.
    Flanigan SA; Pitts TM; Newton TP; Kulikowski GN; Tan AC; McManus MC; Spreafico A; Kachaeva MI; Selby HM; Tentler JJ; Eckhardt SG; Leong S
    Clin Cancer Res; 2013 Nov; 19(22):6219-29. PubMed ID: 24045180
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Compensatory insulin receptor (IR) activation on inhibition of insulin-like growth factor-1 receptor (IGF-1R): rationale for cotargeting IGF-1R and IR in cancer.
    Buck E; Gokhale PC; Koujak S; Brown E; Eyzaguirre A; Tao N; Rosenfeld-Franklin M; Lerner L; Chiu MI; Wild R; Epstein D; Pachter JA; Miglarese MR
    Mol Cancer Ther; 2010 Oct; 9(10):2652-64. PubMed ID: 20924128
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enhancement of doxorubicin cytotoxicity of human cancer cells by tyrosine kinase inhibition of insulin receptor and type I IGF receptor.
    Zeng X; Zhang H; Oh A; Zhang Y; Yee D
    Breast Cancer Res Treat; 2012 May; 133(1):117-26. PubMed ID: 21850397
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The SGLT2 Inhibitor Luseogliflozin Rapidly Normalizes Aortic mRNA Levels of Inflammation-Related but Not Lipid-Metabolism-Related Genes and Suppresses Atherosclerosis in Diabetic ApoE KO Mice.
    Nakatsu Y; Kokubo H; Bumdelger B; Yoshizumi M; Yamamotoya T; Matsunaga Y; Ueda K; Inoue Y; Inoue MK; Fujishiro M; Kushiyama A; Ono H; Sakoda H; Asano T
    Int J Mol Sci; 2017 Aug; 18(8):. PubMed ID: 28777298
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Metabolic recovery of lipodystrophy, liver steatosis, and pancreatic β cell proliferation after the withdrawal of OSI-906.
    Tajima K; Shirakawa J; Togashi Y; Yamazaki S; Okuyama T; Kyohara M; Konishi H; Terauchi Y
    Sci Rep; 2017 Jun; 7(1):4119. PubMed ID: 28646158
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A novel, potent, and selective insulin-like growth factor-I receptor kinase inhibitor blocks insulin-like growth factor-I receptor signaling in vitro and inhibits insulin-like growth factor-I receptor dependent tumor growth in vivo.
    Ji QS; Mulvihill MJ; Rosenfeld-Franklin M; Cooke A; Feng L; Mak G; O'Connor M; Yao Y; Pirritt C; Buck E; Eyzaguirre A; Arnold LD; Gibson NW; Pachter JA
    Mol Cancer Ther; 2007 Aug; 6(8):2158-67. PubMed ID: 17671083
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Luseogliflozin attenuates neointimal hyperplasia after wire injury in high-fat diet-fed mice via inhibition of perivascular adipose tissue remodeling.
    Mori Y; Terasaki M; Hiromura M; Saito T; Kushima H; Koshibu M; Osaka N; Ohara M; Fukui T; Ohtaki H; Tsutomu H; Yamagishi SI
    Cardiovasc Diabetol; 2019 Oct; 18(1):143. PubMed ID: 31672147
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of p70S6K1 Activation by Pdcd4 Overcomes the Resistance to an IGF-1R/IR Inhibitor in Colon Carcinoma Cells.
    Zhang Y; Wang Q; Chen L; Yang HS
    Mol Cancer Ther; 2015 Mar; 14(3):799-809. PubMed ID: 25573956
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Glucose effects on beta-cell growth and survival require activation of insulin receptors and insulin receptor substrate 2.
    Assmann A; Ueki K; Winnay JN; Kadowaki T; Kulkarni RN
    Mol Cell Biol; 2009 Jun; 29(11):3219-28. PubMed ID: 19273608
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 18FDG-PET predicts pharmacodynamic response to OSI-906, a dual IGF-1R/IR inhibitor, in preclinical mouse models of lung cancer.
    McKinley ET; Bugaj JE; Zhao P; Guleryuz S; Mantis C; Gokhale PC; Wild R; Manning HC
    Clin Cancer Res; 2011 May; 17(10):3332-40. PubMed ID: 21257723
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Insulin receptor (IR) pathway hyperactivity in IGF-IR null cells and suppression of downstream growth signaling using the dual IGF-IR/IR inhibitor, BMS-754807.
    Dinchuk JE; Cao C; Huang F; Reeves KA; Wang J; Myers F; Cantor GH; Zhou X; Attar RM; Gottardis M; Carboni JM
    Endocrinology; 2010 Sep; 151(9):4123-32. PubMed ID: 20610571
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.